Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study

2026-03-07 05:24:41

Pfizer Inc. is initiating a new real-world observational study in Taiwan to evaluate the effectiveness of its multiple myeloma drug, elranatamab, in a routine hospital environment. This study aims to collect data on actual patient outcomes and treatment patterns, supporting the drug’s longer-term acceptance and market share in Asia. While the study is not yet recruiting, its progress indicates Pfizer’s commitment to its oncology portfolio, with potential positive impacts on pricing and reimbursement discussions in the future.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.